Corcept Therapeutics (CORT) Tops Q2 EPS by 10c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $81.93 --0%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.29, $0.10 better than the analyst estimate of $0.19. Revenue for the quarter came in at $194.4 million versus the consensus estimate of $199.4 million.
GUIDANCE:
Corcept Therapeutics sees FY2025 revenue of $850-900 million, versus the consensus of $899 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- Nucor (NUE) PT Raised to $301 at KeyBanc
- KeyBanc on Metallus Inc. (MTUS): 'Trimming Estimates on 4Q26 Outlook'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
